Considering Reprogenomics in the Ethical Future of Fetal Therapy Trials
- PMID: 35258428
- PMCID: PMC9912160
- DOI: 10.1080/15265161.2022.2027558
Considering Reprogenomics in the Ethical Future of Fetal Therapy Trials
Comment in
-
A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials: Response to Commentaries.Am J Bioeth. 2022;22(3):W1-W3. doi: 10.1080/15265161.2022.2044563. Epub 2022 Mar 8. Am J Bioeth. 2022. PMID: 37180307 Free PMC article. No abstract available.
-
Fetal Therapies and Clinical Research: Beyond Risk and Benefit.Am J Bioeth. 2022 Mar;22(3):1-3. doi: 10.1080/15265161.2022.2035468. Epub 2022 Mar 8. Am J Bioeth. 2022. PMID: 38410955 No abstract available.
-
What Lies Beneath the Framework: The Importance of Grounding Ethical Discussions of Maternal-Fetal Therapy.Am J Bioeth. 2022 Mar;22(3):73-75. doi: 10.1080/15265161.2022.2027563. Epub 2022 Mar 8. Am J Bioeth. 2022. PMID: 38410994 No abstract available.
Comment on
-
A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials.Am J Bioeth. 2022 Mar;22(3):45-61. doi: 10.1080/15265161.2020.1867932. Epub 2021 Jan 16. Am J Bioeth. 2022. PMID: 33455521 Free PMC article.
References
-
- Farrell Ruth M, Michie Marsha, Scott Christopher, Flyckt Rebecca, LaPlante Mary. 2019. “Prioritizing Women’s Health in Germline Editing Research.” AMA Journal of Ethics, 21(12):E1071–1078. - PubMed
-
- Hendriks Saskia, Grady Christine, Wasserman David, Wendler David, Bianchi Diana W., and Berkman Benjamin E. 2021. “A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy Trials.” The American Journal of Bioethics, January, 1–25. 10.1080/15265161.2020.1867932. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources